ADMA News and Press, ADMA Biologics Inc From 02/12/19

ADMA Biologics (NASDAQ: ADMA ) has entered into a senior secured term loan facility with Perceptive Advisors for up to $72.5M under two funding tranches. More news on: ADMA Biologics Inc, Healthcare stocks news, Stocks on the move, Read more ...

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 12, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops s...

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops s...

On December 19th, ADMA Biologics ( ADMA ) received a complete response letter ((CRL)) from the FDA in regards to the Prior Approval Submission ((PAS)) for their intravenous human immunoglobulin ((IVIG)) product, BIVIGAM. This came as surprise to investors due to the company receiving an imp...

The FDA has accepted for review ADMA Biologics' (NASDAQ: ADMA ) resubmitted BLA seeking approval for lead candidate RI-002 for the treatment of patients with primary immune deficiency disease (PIDD). It received a CRL in July 2016 in response to its original filing. More news on: ADMA Bi...

Resubmission of Biologics License Application (“BLA”) Reinforces the Company’s Commitment to Commercialize Novel Therapies for Immune Compromised Patients to Address Unmet Medical Needs RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2018 (GLOBE NEWSWIRE) -- ADMA Bio...

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 11, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops s...

ADMA Biologics (NASDAQ: ADMA ) announces that the Company’s wholly-owned subsidiary, ADMA BioCenters, has received FDA approval for its third plasma collection center, located at 166 Ernest W Barrett Parkway, NW, Marietta, Georgia. More news on: ADMA Biologics Inc, Dominion Energy...

RAMSEY, N.J. and MARIETTA, Ga., Oct. 03, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for...

ADMA Biologics (NASDAQ: ADMA ) has responded to the July 2016 Complete Response Letter (“CRL”) and resubmitted its Biologics License Application (“BLA”) for RI-002 to the FDA on September 28, 2018. More news on: ADMA Biologics Inc, Healthcare stocks news, Stoc...